公开(公告)号：US20100092549A1

公开(公告)日：2010-04-15

申请号：US12526326

申请日：2008-02-11

申请人： Sandra Blundell ,  Panagiotis Keramidas ,  Brett Antony Mooney ,  Todd James Rutherford

发明人： Sandra Blundell ,  Panagiotis Keramidas ,  Brett Antony Mooney ,  Todd James Rutherford

IPC分类号： A61K9/48 ,  A61K31/5513

CPC分类号： A61K9/4866 ,  A61K9/2018 ,  A61K9/2072 ,  A61K9/5084 ,  A61K31/135 ,  A61K31/551

摘要： A dosage form for administration of two or more active pharmaceutical ingredients to a subject, comprising a first pharmaceutical composition comprising a first active pharmaceutical ingredient and optionally one or more pharmaceutically acceptable excipients in a first physical form selected from the group consisting of powder, granule, pellet, bead or mini-tablet form, and at least a second pharmaceutical composition comprising a second active pharmaceutical ingredient and optionally one or more pharmaceutically acceptable excipients in a second physical form selected from the group consisting of granule, pellet, bead, mini-tablet or tablet form, wherein the composition is characterised in that said first and second physical forms are selected to be different to minimise interactions between said first and second pharmaceutical compositions and to allow separation of said first and second pharmaceutical compositions for analysis on the basis of size difference.

摘要翻译： 用于向受试者施用两种或更多种活性药物成分的剂型，其包含第一药物组合物，所述第一药物组合物包含第一活性药物成分和任选的一种或多种药学上可接受的赋形剂，所述第一物理形式选自粉末，颗粒， 丸剂，珠粒或迷你片剂形式，以及至少第二药物组合物，其包含第二活性药物成分和任选的一种或多种药学上可接受的赋形剂，所述第二物理形式选自颗粒，丸粒，珠粒，迷你片 或片剂形式，其中所述组合物的特征在于，所述第一和第二物理形式被选择为不同以使所述第一和第二药物组合物之间的相互作用最小化，并允许基于尺寸分离所述第一和第二药物组合物用于分析 区别。

公开(公告)号：US09095519B2

公开(公告)日：2015-08-04

申请号：US12526326

申请日：2008-02-11

申请人： Sandra Blundell ,  Panagiotis Keramidas ,  Brett Antony Mooney ,  Todd James Rutherford

发明人： Sandra Blundell ,  Panagiotis Keramidas ,  Brett Antony Mooney ,  Todd James Rutherford

IPC分类号： A61K9/48 ,  A61K9/20 ,  A61K9/50 ,  A61K31/135 ,  A61K31/551

CPC分类号： A61K9/4866 ,  A61K9/2018 ,  A61K9/2072 ,  A61K9/5084 ,  A61K31/135 ,  A61K31/551

摘要： A dosage form for administration of two or more active pharmaceutical ingredients to a subject, comprising a first pharmaceutical composition comprising a first active pharmaceutical ingredient and optionally one or more pharmaceutically acceptable excipients in a first physical form selected from the group consisting of powder, granule, pellet, bead or mini-tablet form, and at least a second pharmaceutical composition comprising a second active pharmaceutical ingredient and optionally one or more pharmaceutically acceptable excipients in a second physical form selected from the group consisting of granule, pellet, bead, mini-tablet or tablet form, wherein the composition is characterized in that said first and second physical forms are selected to be different to minimize interactions between said first and second pharmaceutical compositions and to allow separation of said first and second pharmaceutical compositions for analysis on the basis of size difference.

摘要翻译： 用于向受试者施用两种或更多种活性药物成分的剂型，其包含第一药物组合物，所述第一药物组合物包含第一活性药物成分和任选的一种或多种药学上可接受的赋形剂，所述第一物理形式选自粉末，颗粒， 丸剂，珠粒或迷你片剂形式，以及至少第二药物组合物，其包含第二活性药物成分和任选的一种或多种药学上可接受的赋形剂，所述第二物理形式选自颗粒，丸粒，珠粒，迷你片 或片剂形式，其中所述组合物的特征在于，所述第一和第二物理形式被选择为不同以使所述第一和第二药物组合物之间的相互作用最小化，并允许基于尺寸分离所述第一和第二药物组合物用于分析 区别。